Cargando…

Cancer Classification at the Crossroads

Internationally accepted classifications of malignant tumors, developed by the World Health Organization (WHO) and the Union for International Cancer Control (UICC), are based on the histotype, site of origin, morphologic grade, and spread of cancer throughout the body. The WHO classifications are t...

Descripción completa

Detalles Bibliográficos
Autor principal: Carbone, Antonino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226085/
https://www.ncbi.nlm.nih.gov/pubmed/32326638
http://dx.doi.org/10.3390/cancers12040980
_version_ 1783534206148673536
author Carbone, Antonino
author_facet Carbone, Antonino
author_sort Carbone, Antonino
collection PubMed
description Internationally accepted classifications of malignant tumors, developed by the World Health Organization (WHO) and the Union for International Cancer Control (UICC), are based on the histotype, site of origin, morphologic grade, and spread of cancer throughout the body. The WHO classifications are the foundation of cancer diagnosis and the starting point for cancer management. Starting in 2000, the WHO classifications began to include biologic and molecular–genetic features. These developments are having a strong impact on cancer diagnosis and treatment, and this impact is amplifying, given the advances in cancer genomics. Molecular–genetic profiling can be used to refine existing classifications of tumors and, for a small but increasing number of cancers, even determine the treatment irrespective of histotype. Here I discuss how cancer classifications may change in the era of cancer genomics.
format Online
Article
Text
id pubmed-7226085
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72260852020-05-18 Cancer Classification at the Crossroads Carbone, Antonino Cancers (Basel) Perspective Internationally accepted classifications of malignant tumors, developed by the World Health Organization (WHO) and the Union for International Cancer Control (UICC), are based on the histotype, site of origin, morphologic grade, and spread of cancer throughout the body. The WHO classifications are the foundation of cancer diagnosis and the starting point for cancer management. Starting in 2000, the WHO classifications began to include biologic and molecular–genetic features. These developments are having a strong impact on cancer diagnosis and treatment, and this impact is amplifying, given the advances in cancer genomics. Molecular–genetic profiling can be used to refine existing classifications of tumors and, for a small but increasing number of cancers, even determine the treatment irrespective of histotype. Here I discuss how cancer classifications may change in the era of cancer genomics. MDPI 2020-04-15 /pmc/articles/PMC7226085/ /pubmed/32326638 http://dx.doi.org/10.3390/cancers12040980 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Perspective
Carbone, Antonino
Cancer Classification at the Crossroads
title Cancer Classification at the Crossroads
title_full Cancer Classification at the Crossroads
title_fullStr Cancer Classification at the Crossroads
title_full_unstemmed Cancer Classification at the Crossroads
title_short Cancer Classification at the Crossroads
title_sort cancer classification at the crossroads
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226085/
https://www.ncbi.nlm.nih.gov/pubmed/32326638
http://dx.doi.org/10.3390/cancers12040980
work_keys_str_mv AT carboneantonino cancerclassificationatthecrossroads